An effective vaccine against Pseudomonas aeruginosa would be hugely beneficial to people who are susceptible to the serious infections it can cause. Vaccination against PcrV of the P. aeruginosa type III secretion system is a potential prophylactic strategy for improving the incidence and prognosis of P. aeruginosa pneumonia. Here, the effect of nasal PcrV adjuvanted with CpG oligodeoxynucleotide (CpG) was compared with a nasal PcrV/aluminum hydroxide gel (alum) vaccine. Seven groups of mice were vaccinated intranasally with one of the following: 1, PcrV-CpG; 2, PcrV-alum; 3, PcrV alone; 4, CpG alone; 5, alum alone; 6 and 7, saline control. Fifty days after the first immunization, anti-PcrV IgG, IgA and IgG isotype titers were measured; significant increases in these titers were detected only in the PcrV-CpG vaccinated mice. The vaccinated mice were then intratracheally infected with a lethal dose of P. aeruginosa and their body temperatures and survival monitored for 24 hr, edema, bacteria, myeloperoxidase activity and lung histology also being evaluated at 24 hr post-infection. It was found that 73% of the PcrV-CpG-vaccinated mice survived, whereas fewer than 30% of the mice vaccinated with PcrV-alum or adjuvant alone survived. Lung edema and other inflammation-related variables were less severe in the PcrV-CpG group. The significant increase in PcrV-specific IgA titers detected following PcrV-CpG vaccination is probably a component of the disease protection mechanism. Overall, our data show that intranasal PcrV-CpG vaccination has potential efficacy for clinical application against P. aeruginosa pneumonia.
Pseudomonas aeruginosa is one of the major bacterial pathogens responsible for pneumonia in high-risk individuals, such as those undergoing artificial ventilation or with cystic fibrosis. The increasing problems of antibiotic resistance and rapidly aging populations in advanced countries means that an effective vaccine against this opportunistic pathogen has long been eagerly awaited (1) . In recent years, several vaccine candidates have been assessed in phase I and II clinical studies; however, no vaccine against this bacterium is clinically available yet (2, 3) . Some of the difficulties in developing an effective P. aeruginosa vaccine relate to the diverse virulence-associated molecules in this bacterium, which lead to multiple virulence mechanisms and many types of infections. Factors associated with host immunity, such as neutropenia in patients with cancer, impaired barriers in patients with burns or receiving artificial ventilation, and impaired lung clearance mechanisms in individuals with cystic fibrosis, also contribute to development of various pathologies ranging from colonization to severe infections in these patients, which complicates conduction of clinical trials. Because safety and prophylactic effectiveness are both crucially important features in vaccine development, a vaccine trial must minimize the risk of inducing immunologically-mediated damage. Therefore, in addition to selection of the ideal vaccine antigen, the choice of immune boosting adjuvant and vaccine administration route are also very important.
Targeting the PcrV protein of the P. aeruginosa TTSS by vaccination is one of the on-going experimental avenues on which we have reported (4) (5) (6) . Through the TTSS, bacteria can directly translocate their toxins into the cytosol of target eukaryotic cells to hijack intracellular signaling (7) . In the case of P. aeruginosa, four type III secretory toxins, ExoS, ExoT, ExoU and ExoY have been identified (8) . Among them, ExoU, which has bacterial patatin-like phospholipase A 2 activity (9, 10), has been identified as the major cytotoxin that induces cell death in the lungs and fatal pathophysiology, such as bacteremia and sepsis (11, 12) . Therefore, blocking ExoU translocation has great potential for reducing lethal outcomes of P. aeruginosa pneumonia.
In our research aimed at impeding toxin translocation through the TTSS, we identified the molecular target PcrV, which is the cap structure of an injection needle in the type III secretion apparatus (13) (14) (15) . In past studies performed by us and others, vaccination with recombinant PcrV decreased the mortality of healthy and immunocompromised mice infected with a lethal dose of virulent P. aeruginosa (4) (5) (6) . We recently tested the adjuvanted effects of the TLR 9 agonist CpG ODN via intraperitoneal vaccination of PcrV and found that the effects of PcrV-CpG vaccine and PcrV-alum vaccine were comparable in a murine model of P. aeruginosa pneumonia (4) . Here, we tested intranasal administration of the PcrV-CpG vaccine against the PcrV-alum vaccine to assess its potential clinical application in those at high risk of contracting P. aeruginosa infection.
MATERIALS AND METHODS

Construction of recombinant tagless PcrV and adjuvants
The PcrV coding sequence was PCR-amplified from the P. aeruginosa PAO1 chromosome with a specific primer set (SphI-PcrV5 primer: 5 0 -G CAT GCG AAA ATG GAA GTC AGA AA-3 0 , and HindIII-PcrV3 primer: 5 0 -A AGC TTG CTA GAT CGC GCT GAG AA-3 0 ). The PCR amplicon was purified, treated with SphI and HindIII restriction enzymes and ligated to the cloning site of an Escherichia coli expression vector (32932, TAGZyme pQE-2; Qiagen, Hilden, Germany) to create an expressed protein containing a hexahistidine tag with a methionine-lysine motif at the amino-terminal. The expression vector was introduced into the E. coli M15 strain (32149, QIAexpress Type IV Kit; Qiagen) and recombinant PcrV expression induced by adding 0.5 mM isopropylthio-bgalactoside. The PcrV-containing lysate from E. coli cells was purified using nickel-nitrilotriacetic acid agarose columns (Novex R901-15; Thermo Fisher Scientific, Waltham, MA, USA), dialyzed for 72 hr against PBS, and then applied to resin endotoxin removal columns (Pierce 88270; Thermo Fisher Scientific). Subsequently, the amino-terminal hexahistidine tag of the recombinant PcrV was removed using exopeptidases (34362, TAGZyme DAPase Enzyme; Qiagen). After exopeptidase digestion, the residual undigested proteins were removed by nickel-nitrilotriacetic acid agarose column separation. Confirmation of expression of the tagless recombinant PcrV was confirmed by SDS-PAGE and an in-gel hexahistidine-tag detection system (08500-94, His-Detect In-Gel Stain; Nacalai Tesque, Kyoto, Japan).
Aluminum hydroxide gel (alum, 20 mg/mL) was purchased from Wako Pure Chemical Industries (Kyoto, Japan). The CpG K type (K3) ODN (5 0 -ATC GAC TCT GGA GGG TTC TC-3 0 ) was synthesized by GeneDesign (Ibaraki, Japan) (16) and the resultant solid CpG ODN dissolved in saline at 1 mg/mL.
Immunizations
Certified pathogen-free, male ICR mice (4 weeks old) were purchased from Shimizu Laboratory Supplies (Kyoto, Japan). The mice were housed in cages with filter tops under pathogen-free conditions. The protocols for all animal experiments were approved by the Animal Research Committee of Kyoto Prefectural University of Medicine, Kyoto, Japan, prior to undertaking the experiments (authorization number: M28-531).
Recombinant PcrV (rePcrV, 10 mg/dose) was administered alone or in combination with one of the following adjuvants: CpG ODN (10 mg/dose) or alum (15 mL/ dose), in a total volume of 30 mL saline. The day before the immunizations were administered, rePcrV and alum were mixed and slowly rotated overnight to assist their conjugation. Under light sevoflurane anesthesia, four groups of mice were immunized intranasally with either PcrV-CpG, PcrV-alum, PcrV alone or saline (noninfection series). A further five groups were immunized with either PcrV-CpG, PcrV-alum, PcrV alone, CpG Nasal vaccine for P. aeruginosa ODN (10 mg/dose) alone or alum (15 mL/dose) alone; these mice comprised the infection series, along with a final two groups of mice that received saline only (Table 1) . On Days 7, 14 and 21 post-immunization, the same vaccine formulations were administered to the mice as booster immunizations (Fig. 1) . Additionally, a non-infection series that received two sets of vaccination (each set consisted of 15 mice that were assigned to three groups) were carried out on two separate days to check the reproducibility of vaccination effects. Outcome data (anti-PcrV titers) were derived from the total sum of two separate experiments, each of which consisted of three vaccination groups. Further, an infection series received five sets of vaccination (each set consisted of 11 to 20 mice that were assigned to two to three groups), followed by infection challenges on five separate days. Outcome data (anti-PcrV titers, survival, body temperature, lung weights, myeloperoxidase assay, and bacteriology) were derived from the total sum of five separate experiments, each of which consisted of two to three vaccination groups. The total sum of each group was derived from at least two separate experiments carried out with sets of mice that were vaccinated on two different days to check the reproducibility of vaccination effects.
Bronchoalveolar lavage
Mice were killed humanely by intraperitoneal injection of a large dose of pentobarbital, after which tracheostomy was performed. BAL was performed by slowly injecting 0.8 mL of PBS into the lungs through the catheter inserted into the trachea, followed by aspiration to recover the lavage fluid.
Measurement of anti-PcrV immunoglobulin titer
On Day 50 post-immunization, peripheral blood samples and BAL fluids were collected from the first series of humanely killed, vaccinated mice (noninfection series). BAL fluids collected from the vaccinated mice in the first series were diluted 1:10 with saline. Peripheral blood samples were collected from the tail veins of the immunized mice in the second series (infection series) on Day 50, prior to infection on Day 55. The collected blood was diluted 1:1,000 with saline. In the second series of vaccinated mice, lung homogenate supernatants were collected and diluted 1:2 with saline. To evaluate antibody responses to vaccination, PcrVspecific IgG titers and PcrV-specific antibody isotypes were measured by ELISA. rePcrV was diluted to 1 mg/mL with coating buffer (0.1 mM NaHCO 3 , pH 8.2). Microtiter plates (430341, Nunc C96 Maxisorp; Thermo Fisher Scientific) were coated with 50 mL per well of the diluted antigen and then incubated at 4°C overnight. The plates were washed twice with monolaurate (161-25521, PBS/T; Wako Pure Chemical Industries), and then blocked with 200 ml per well of PBS containing 1% bovine serum albumin at 37°C for 2 hr. After washing twice with PBS/T, 100 mL of each serum sample was added to each well and the plates incubated at 4°C overnight. The plates were then washed four times, after which 100 mL per well of either goat anti-mouse IgG (whole molecule)-peroxidase antibody (A8924; Sigma-Aldrich, St. Louis, MO, USA), diluted 1:20,000, or goat anti-mouse IgA a chain antibody conjugated to HRP (ab97235; Abcam, Cambridge, UK), diluted 1:25,000, was added to detect the attached antibodies. After incubation at 37°C for 1 hr, the plates were washed six times, after which 200 mL per well of 3,3 0 ,5,5 0 -tetramethylbenzidine liquid substrate system for ELISA (T0440; Sigma-Aldrich) was added to visualize the antibody complexes. The plates were incubated at room temperature for 30 min before the reaction was stopped with 100 mL per well of 0.5 M sulfuric acid and the OD at 450 nm measured by a microplate reader (MTP-880Lab; Corona Electric, Hitachinaka, Japan).
PcrV-specific antibody isotype activation by the vaccines was also evaluated in the same groups of mice before infection challenge. The microtiter plates were coated and blocked and serum samples added the same as for the total IgG titer measurements. Plates were washed before addition of 100 mL IgG 1 -, IgG 2a -, IgG 2b -or IgG 3 -specific goat anti-mouse mAb isotyping reagents (ISO2; Sigma-Aldrich) diluted 1:1,000. After incubation at room temperature for 30 min and washing four times with PBS/ T, 100 mL per well of rabbit anti-goat IgG (whole molecule)-peroxidase antibody (A8919; Sigma-Aldrich) diluted 1:20,000 was added to each well. The plates were incubated at room temperature for 15 min and washed six times with PBS/T before the antibody complexes were visualized as described above. All samples were measured in duplicate and the absorbance values averaged.
Intratracheal infection with P. aeruginosa P. aeruginosa PA103 strain (ATCC 29260) was used for intratracheal infection. This laboratory strain produces significant amounts of the type III secretory toxins ExoU and ExoT (10), but fails to secrete ExoY (17), and does not have the exoS TTSS genotype (18) . Suspensions of PA103 were prepared as described previously (19) . Cultures were grown at 32°C for 12 hr in a shaking incubator and then centrifuged at 3000 g for 10 min. The bacterial pellets were washed twice in 0.9% saline and then diluted to the appropriate number of CFUs/mL, as determined by spectrophotometry. Bacterial counts were confirmed by determining CFU numbers from a diluted aliquot on a sheep blood agar plate. On Day 55 post immunization, mice under light sevoflurane anesthesia were infected intratracheally with PA103 (1.5 Â 10 6 CFU in 60 mL of saline) using an endotracheal needle, as described previously (20) . The mice recovered from the anesthesia within 20 s. One of the two groups of saline-only immunized mice was not infected with PA103 but received saline only intratracheally. Mouse body temperatures (a single measurement at each time point) and survival were monitored for 24 hr. Of note, the mice were observed for only 24 hr, because in our previous experiments using this acute infection model (6), the vaccinated mice that survived for 24 hr after infection challenge were generally able to survive for more than one week. At 24 hr post-infection, the surviving mice were killed humanely and lungs from both infection survivors and nonsurvivors and blood from surviving mice collected. The weights of the lungs were immediately measured once, after which the lungs were homogenized with 1 mL of saline in a homogenizer (Polytron PT10/35; Kinematica, Luzern, Switzerland) for further evaluation.
Bacteriological assays
One hundred microliter of lung homogenates was sequentially diluted with sterile saline. The diluents (100 mL/each) were then inoculated onto sheep blood agar plates and incubated at 37°C overnight. The total number of bacteria in the lungs was estimated by calculating the average CFU counts on multiple plates.
Lung edema and myeloperoxidase assays
Myeloperoxidase activity in the lung homogenates was measured as follows. The homogenates were centrifuged at 10,000 g at 4°C for 15 min. After removing the supernatant, KH 2 PO 4 (working solution buffered to pH 6.0) and 50 mM of hexadecyltrimethylammonium bromide (1102974; Sigma-Aldrich) were added to the precipitate. The mixture was processed by repeated sonication and three freeze-thawing cycles, centrifuged at 10,000 g at 4°C for 10 min and the supernatant collected. Supernatant samples (diluted in 1:4) were added at 10 mL per well to microtiter plates and 290 mL per well of the working buffer containing 0.167 mg/mL of 3,3 0 -dimethoxybenzidine dihydrochloride (Wako Pure Chemical Industries) and 0.001% H 2 O 2 added to each well. After incubation at room temperature for 1 min, the OD at 450 nm was measured. All samples were measured in duplicate and the absorbance values averaged.
Lung histology
Lungs were collected for histological analysis from one vaccinated mouse from the non-infection series, one dead mouse (a saline-or alum alone-treated mouse) from the infection series within 24 hr of intratracheal instillation of P. aeruginosa, and one designated mouse that had been killed 24 hr after intratracheal instillation of P. aeruginosa. The lungs were fixed with a 10% formalin neutral-buffered solution, embedded in paraffin and mounted sections (frontal longitudinal slices) stained with hematoxylin and eosin. Several typical microscopic views from each group were photographed.
Statistical analyses
The Kaplan-Meier estimator and log-rank test were used to assess mouse survival. One-way anova and Tukey's multiple comparison tests were used to compare body temperatures, anti-PcrV IgG anti-PcrV IgA titers, lung weights and MPO activities. Kruskal-Wallis non-parametric and Dunn's multiple comparison tests were used for comparing bacterial numbers in the lungs. P < 0.05 was considered to denote statistical significance. All statistical analyses were performed using Prism version 7.03 (GraphPad Software, La Jolla, CA, USA). Data are presented as mean values AE SD, or median value (central solid bar in the box), first (boxes) and second quartiles (bars), individual mice being indicated by circles.
RESULTS
Anti-PcrV titers induced by nasal administration of adjuvanted PcrV vaccines
Under our vaccination protocol (Fig. 1) , four groups of mice in the non-infection series and seven groups in the infection series were examined to determine the adjuvant effects of CpG ODN and alum (Table 1) . After receiving booster vaccinations on Days 7, 14 and 21, anti-PcrV IgG in sera and anti-PcrV IgG and IgA in BAL fluids were measured in the non-infection series of vaccinated mice on Day 50 post-immunization. Concurrently, anti-PcrV IgG was measured in the sera of the infection series of vaccinated mice. To evaluate the type of protective immunity induced, IgG isotype titers specific for PcrV were also measured. Anti-PcrV IgG titers were significantly higher in the sera from the PcrV-CpG group than in sera from all other groups in the non-infection series ( Ã P < 0.05) (Fig. 2a) . Both anti-PcrV IgG and anti-PcrV IgA titers in BAL fluids were also significantly higher in the PcrV-CpG vaccinated mice than in those of the other groups ( Ã P < 0.05) (Fig. 2b, c) . On examination of lung histology, neither inflammation nor injury was detected in the four groups of vaccinated mice in the non-infection series (Fig. 3a) . As with the non-infection series of mice, serum anti-PcrV IgG titers were significantly higher in the PcrV-CpG group from the infection series than in all other groups from this series ( Ã P < 0.05) (Fig. 4a) . Administration of PcrV alone or adjuvant alone did not result in increased anti-PcrV titers. Although a few mice in the PcrV-alum group demonstrated increased antiPcrV titers, anti-PcrV IgG titers were not significantly higher in this group than in the other control groups. Analysis of the serum anti-PcrV IgG isotypes in the infection series of mice showed statistically significant increases in PcrV-specific IgG 1 , IgG 2a , and IgG 2b in the PcrV-CpG vaccinated mice (Fig. 4b) . 
Survival rates and body temperatures
On Day 55 after the first vaccination, the second (infection) series of vaccinated mice, excluding the saline-only control group, were infected intratracheally with a lethal dose of the P. aeruginosa PA103 strain and the body temperatures and survival of all mice monitored for 24 hr (Fig. 5) . Of the mice that received intranasal PcrV-CpG, 73% recovered from the initial hypothermia after infection and survived for 24 hr. At 8 hr postinfection, the body temperatures of the survivors in the PcrV-CpG group recovered from the initial hypothermia significantly more frequently than did those of the salinetreated infected group ( Ã P < 0.05) and PcrV-alum and PcrV alone groups. ( ‡P < 0.05). None of the mice treated with saline or alum alone recovered from their initial hypothermia; all died within 24 hr. Only 29%, 20%, and 20% of the mice vaccinated with PcrV-alum, PcrV alone, or CpG ODN alone, respectively, recovered from their hypothermia and survived for 24 hr. Among the vaccinated groups, only the PcrV-CpG group had a significantly higher survival rate than the other infected groups ( Ã P < 0.05 vs. saline-treated infected group, ‡P < 0.05 vs. PcrV-alum and PcrV alone groups). 
Lung edema, bacteriology, MPO activity and anti-PcrV IgA titers in the lungs
Lung edema was evaluated as wet lung weight at 24 hr post-infection in the infection series of mice (Fig. 6a) . The average lung weight in the saline-treated uninfected group was 0.18 AE 0.01 g (mean AE SD). At 24 hr post bacterial instillation, the average lung weight of the infected animals was significantly greater than that in the saline-treated, uninfected mice ( †P < 0.05, compared with the uninfected, saline-treated mice). The PcrV-CpG group had a significantly lower average lung weight than did the other infected groups ( Ã P < 0.05 vs. the salinetreated infected, ‡P < 0.05 vs. CpG alone and alum alone groups).
To evaluate the severity of lung inflammation, neutrophil recruitment was quantitatively measured by MPO activity assay in lung homogenates at 24 hr post bacterial instillation in the infection series of mice. MPO activity was significantly greater in all infected groups than in the saline-treated uninfected group (Fig. 6b) ( †P < 0.05 compared with the saline uninfected group). Compared with the saline-treated infected group, the PcrV-CpG group had significantly weaker MPO activity ( Ã P < 0.05). The PcrV-CpG group showed weaker MPO activity than the PcrV-alum and PcrV alone groups ( ‡P < 0.05).
The total number of bacteria in the lungs was measured in all the mice in the infection series, including those that had died by 24 hr post bacterial instillation (Fig. 6c) . Although the PcrV-CpG group had lower bacterial counts than the other groups, there were no statistically significant differences between the groups.
Anti-PcrV IgA titers in lung homogenates were also measured (Fig. 4c) . Anti-PcrV IgA titers were significantly higher in the PcrV-CpG group than in the other six groups ( Ã P < 0.05); indeed, no other groups showed increased anti-PcrV IgA titers. PcrV alone groups. The data were derived from the sum of five separate experiments (performed on five separate days), each of which consisted of two to three vaccination groups.
Lung histology after infection
Histological changes in the lungs were evaluated at 24 hr post bacterial instillation in the infection series of mice. Enhanced neutrophil infiltration, alveolar hemorrhage, and destruction of the alveolar structure were observed in the lungs of the PcrV-alum, PcrV alone, adjuvant alone, and saline-treated infection groups (Fig. 7) . The lungs from the PcrV-CpG group displayed qualitatively less inflammatory changes than was observed in the other groups.
DISCUSSION
From the various immunization strategies designed to tackle P. aeruginosa infection (21), we have focused on blocking the TTSS of this bacterium (13) . In previous experiments, we showed that blocking the TTSS through anti-PcrV enhances the opsonophagocytic activity of macrophages because type III secretory toxins, such as ExoT and ExoU, are anti-phagocytic factors (6) . Using specific anti-PcrV antibodies to block PcrV function limits the ability of P. aeruginosa to kill eukaryotic cells, with the added bonus of reducing inflammatory cytokine release (6, 15, (21) (22) (23) ). An engineered humanized antibody targeting PcrV (KB001-A) has been trialed clinically (14) ; however, this trial was not powered for outcome assessments in patients with ventilator-associated pneumonia or cystic fibrosis (24, 25) . Other researchers have also tried to target PcrV using various active or passive immunization approaches (26) (27) (28) . In our past active immunization studies, we have shown that vaccination with PcrV/Freund's adjuvant blocks TTSS-associated virulence in P. aeruginosa pneumonia (5, 6). However, because Freund's adjuvant cannot be used clinically, we have investigated other adjuvants with clinical potential (e.g., aluminum hydroxide and CpG ODN) and found that an intraperitoneally administered PcrV-CpG vaccine induces a comparably protective effect to that induced by PcrValum vaccine in a mouse model of P. aeruginosa pneumonia (4). Therefore, in the present study, we examined the effectiveness of intranasal administration of the PcrV-CpG vaccine and compared it with intranasal PcrV-alum. In previous studies, we administered 200 mL of vaccine solution containing PcrV antigen (10 mg) or alum (100 ml) intraperitoneally three times over 2 months. However, because the nasal cavities of mice cannot accept 200 mL of vaccine solution, administration of the vaccine by the intranasal route necessitated reduction in the volume of vaccine solution (30 mL of vaccine solution containing either 10 mg PcrV or 15 mL alum) to avoid spilling over into the oral cavity. In addition, because some mice cough out the vaccine solution after intranasal administration, we chose a fourdose administration schedule over two months to determine the stability of effect. We found that intranasal administration of PcrV-CpG, which did not induce inflammation in the lungs, significantly increased both anti-PcrV IgG serum titers and anti-PcrV IgG and IgA titers in BAL fluid, while also improving pulmonary edema, pulmonary inflammation, and mouse survival in P. aeruginosa pneumonia. In contrast, nasal PcrV-alum failed to induce effective immunity against P. aeruginosa. Although bacterial clearance from the infected lungs did not increase significantly in the mice vaccinated with PcrV-CpG, blockade of the TTSS may have prevented acute cell death in the lungs and systemic inflammatory responses, likely contributing to an improved survival rate, as we have shown in our previous experiments using a rabbit infection model and an isogenic mutant of P. aeruginosa that lacks ExoU and ExoT secretion (10) . Currently, very few adjuvants are approved for clinical use with vaccine antigens, the commonest of these in both human and veterinary vaccines being aluminum salts such as aluminum phosphate and aluminum hydroxide. Alum adjuvants have been used primarily in diphtheria-tetanus-pertussis and poliomyelitis vaccines; they have also been introduced into hepatitis B virus and human papillomavirus vaccines in recent years (29, 30) . These adjuvants have been used for almost 90 years (31) and are currently licensed by the U.S. Food and Drug Administration for clinical use. Although alum has been widely used for such a long time, the mechanism underlying its immunostimulatory effect is still not fully understood (32) (33) (34) . A recent study found that cell death caused by aluminum and the subsequent release of host cell DNA act as a potent endogenous immunostimulatory signal (35) . Unlike the systemic immune system, mucosal surfaces are constantly exposed to foreign substances; thus, the mucosal immune system must be selective in its targeting to avoid undesirable and excessive immune responses (36, 37) . In the present study, we found that administration of the intranasal PcrV-alum vaccine did not result in increased anti-PcrV titers in the mice and failed to protect them from a lethal dose of P. aeruginosa, suggesting that the aluminum adjuvant in this vaccine did not induce effective mucosal immune responses. Given that intraperitoneal administration of PcrV-alum conferred some degree of protection in our previous study, it is unclear why the intranasally-administered alum-adjuvanted vaccine was not effective. No clinically available vaccine currently uses aluminum as an adjuvant; thus it is possible that aluminum adjuvant is not effective in inducing mucosal immunity.
CpG ODN, a short, single-stranded, synthetic DNA fragment, contains unmethylated CpG dinucleotides in a specific sequence context involving CpG motifs. These CpG motifs are commonly present in the genomes of most bacteria, viruses, and invertebrate animals (38) . CpG ODN mimics the immunostimulatory effects of bacterial DNA and triggers cells that express TLR 9, such as plasmacytoid DCs and B cells (39) . These activated cells produce inflammatory cytokines and activate NK cells, monocytes and neutrophils, leading to activation of a Th1 immune response (38, 40) . In the present study, the increases in anti-PcrV IgG 2a and IgG 1 titers in the PcrV-CpG group suggest the effective induction of Th1 immune responses. It has also been reported that antigen-specific immunity can be induced by mucosal administration of CpG ODN with various antigens (e.g., influenza virus and tetanus toxoid) (41, 42) . Intranasal vaccination is less invasive than injections and can induce both systemic and mucosal immunity (36, 43) . There are plasmacytoid DCs with antigen presentation capacities in the mucosa of the nasopharyngeal tract. When the antigen reaches the plasmacytoid DCs, antigen-specific CD4þ helper T cells are activated to induce differentiation of B cells into IgAproducing plasma cells and this results in secreted IgA at the effector sites (44) . Secreted IgA can bind toxins, bacteria and viruses, thereby neutralizing their activities and preventing them from penetrating the mucosal epithelium. Although intranasal vaccination is an effective strategy for inducing immune responses, it can lead to mucosal tolerance if the immunogenicity of the antigen is weak (40) . Therefore, in addition to selection of the best mucosal route for vaccine administration, an appropriate choice of adjuvant is also essential for effective induction of antigen-specific mucosal immunity. As mentioned above, previous studies have shown that mucosal administration of CpG ODN with some antigens, such as those of influenza virus and tetanus toxoid, efficiently induce antigenspecific immunity (41, 42, 45) . In the present study, the PcrV-CpG group showed significantly higher anti-PcrV IgA titers in BAL fluids and lung homogenates and antiPcrV IgG titers in sera than did the PcrV-alum group, suggesting that PcrV-CpG induces both mucosal and systemic immune responses and that CpG ODN is a suitable adjuvant for increasing the immunogenicity of intranasal vaccination.
Here, we note two limitations of our study. The first relates to the technical challenges of intranasal administration of vaccines to small rodents, in that there is always the potential for such vaccines to spill out of the nasal cavity and enter the oral and/or tracheal cavities. This possibility could be counteracted in future by using larger animals to evaluate specific immune responses induced by nasal administration of vaccines. Second, the immunological mechanisms underlying the advantages of the CpG ODN adjuvant should be investigated to ensure that it invokes effective and safe immune responses. The types of immune response and the duration of the protective effects of this adjuvant in vaccinated animals are of particular interest to scientists and clinicians when considering the clinical use of this vaccine in humans.
Although many other P. aeruginosa vaccine candidates, such as exotoxin A (46), outer membrane proteins including a recombinant OprF/I conjugate (47, 48) , flagella (49) and alginate (50) , have been investigated, there is no licensed vaccine for P. aeruginosa as yet. In the current study, we found that intranasal administration of a PcrV-CpG-based vaccine provides effective protection against virulent P. aeruginosa pneumonia in mice. Therefore, intranasal vaccination with PcrV-CpG has potential to protect people who are at high risk of contracting virulent P. aeruginosa infections. 
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